



Healionics Receives \$200,000 Award from National Institutes of Health

Seattle, WA (July 30, 2010)—Healionics Corporation has received a \$200,000 SBIR grant from the National Institute of General Medical Sciences division of the National Institutes of Health (NIH) for research into reducing infections at dermal exit sites using STAR[®] biomaterial. Healionics' Principal Scientist, Dr. Andrew Marshall, is the Principal Investigator for this research project.

Titled, "Dermal Integration Sleeve to Reduce Exit Site Infections," the award provides one-year funding for further development of cuffs that will greatly improve tissue integration and sealing to percutaneous devices at their skin exit sites. Although there are methods for reducing infections for short-term percutaneous devices, such as applying antimicrobial releasing agents, better solutions are needed for long-term devices. Improved device-to-skin sealing to restore the natural skin barrier provides a promising means to reduce bacterial infection.

Catheters and other percutaneous devices are used in multiple treatment situations, often over long periods. Infections are an ever-present issue; some hundreds of thousands occur each year, with a mortality rate exceeding 30,000 patients in the US alone. With an estimated cost per infection of \$25,000 to \$50,000, the present situation represents a \$6 billion annual cost to US healthcare.

The NIH award will take Healionics a step closer toward the development of an effective cuff to significantly reduce long-term bacterial infections from percutaneous devices. This will potentially have major life saving and cost saving effects.

More information about SBIR grants from the National Institutes of Health can be found at <http://grants.nih.gov/grants/funding/sbir.htm>.

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission is to be the leading provider of tissue regeneration and device biointegration solutions to healthcare manufacturers. The Company's flagship STAR[®] - Sphere Templated Angiogenic Regeneration – biomaterial scaffold is a next generation biomaterial scaffold designed to enhance biointegration and promote healing of implanted medical devices. Healionics Corporation is headquartered in Seattle, Washington. For more information, please visit <http://www.healionics.com>.

###

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com